Sanofi unveils EUROAPI as name of new API company

By Jenni Spinner contact

- Last updated on GMT

Sanofi unveils EUROAPI as name of new API company

Related tags: Sanofi, API, Supply chain, Manufacturing, European union

The global pharmaceutical firm expects big things from its newly formed active pharmaceutical ingredients company, to be led by new CEO Karl Rotthier.

Sanofi has unveiled EUROAPI as the name of its new European active pharmaceutical ingredients (API) company. Additionally, the firm has appointed Karl Rotthier as its future CEO.

According to Sanofi, the new company stands to be the largest API organization in the European Union, with projected sales of approximately €1b ($1.2b USD) by 2022. Additionally, the parent company anticipates EUROAPI will rank first on the continent in small-molecule APIs and second in the global API market.

With concerns about medicine shortages and supply-chain continuity on the rise, EUROAPI leaders reportedly will work toward ensuring additional API capacities for markets in Europe and the rest of the globe, decreasing dependency on APIs sourced from other regions. New CEO Rotthier will be charged with overseeing establishment and growth of the new firm; he most recently served as CEO of Centrient Pharmaceuticals.

Philippe Luscan, executive vice president of global industrial affairs with Sanofi, said company leaders are optimistic about the future of the new API company.

Sanofi is fully committed to the new company’s success, including by establishing a long-term customer relationship with EUROAPI and holding a minority stake of approximately 30% in it,​” Luscan said. “To provide the optimal conditions for success, Sanofi intends the new company to be debt free in order to maximize its future investment capacities​.”

Rotthier, an industry veteran with nearly three decades of experience under his belt, said, “I am particularly delighted to join EUROAPI and look forward to working with my colleagues in creating an agile, stand-alone company, able to unlock its growth potential in a market sustainably growing at a pace of 6% per year. Building on a strong industrial legacy built over decades and broad expertise and experience, EUROAPI would help secure a greater stability in supplying quality drugs to millions of patients worldwide​.”

Initially announced by Sanofi in February 2021, EUROAPI involves creation of a standalone company, which will combine Sanofi’s API commercial and development activities with six of its European production sites: Brindisi in Italy, Frankfurt Chemistry in Germany, Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France).

According to the firm, EUROAPI will offer a range of significant competitive strengths, such as a broad portfolio of 200 APIs with both volume and niche products, high standards of quality and industrial means, competitive pricing and technologies across Europe. Additionally, it will feature a commercial network covering more than 80 countries across the globe.

Related news

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars